Evidence map›Paper›PMID 25866827›Full record

ReviewJournal of immunology research2015

Effect of TACI signaling on humoral immunity and autoimmune diseases.

Yi Zhang, Jun Li, Ya-Min Zhang, Xiao-Ming Zhang, Juan Tao

Open access · goldAbstract readReview
In one paragraph

Review in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Review
  11. Current status of BAFF targeting immunotherapy in B-cell neoplasm.International journal of clinical oncology · 2024
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. [Pemphigus: current and future treatment strategies].Dermatologie (Heidelberg, Germany) · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yi ZhangDepartment of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Jun LiDepartment of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Ya-Min ZhangDepartment of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Xiao-Ming ZhangDepartment of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Juan TaoDepartment of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Union Hospital · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) is one of the receptors of B cell activating factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL). TACI is a regulator in the immune responses. TACI inhibits B cell expansion and promotes the differentiation and survival of plasma cells. The mechanisms underlying these effects probably involve changed expressions of some crucial molecules, such as B lymphocyte induced maturation protein-1 (Blimp-1) and inducible T-cell costimulator ligand (ICOSL) in B cells and/or plasma cells. However, abnormal TACI signaling may relate to autoimmune disorders. Common variable immune deficiency (CVID) patients with heterozygous mutations in TACI alleles increase susceptibility to autoimmune diseases. Taci (-/-) mice and BAFF transgenic mice both develop signs of human SLE. These findings that indicate inappropriate levels of TACI signaling may disrupt immune system balance, thereby promoting the development of autoimmune diseases. In this review, we summarize the basic characteristics of the TACI ligands BAFF and APRIL, and detail the research findings on the role of TACI in humoral immunity. We also discuss the possible mechanisms underlying the susceptibility of CVID patients with TACI mutations to autoimmune diseases and the role of TACI in the pathogenesis of SLE.

Indexed as

AnimalsAutoimmune DiseasesAutoimmunityB-Cell Activating FactorB-LymphocytesCell DifferentiationCommon Variable ImmunodeficiencyCytokinesDNA-Binding ProteinsHumansImmunity, HumoralInducible T-Cell Co-Stimulator LigandMicePositive Regulatory Domain I-Binding Factor 1Repressor ProteinsSignal TransductionB-Cell Activating FactorCytokinesDNA-Binding ProteinsICOSLG protein, humanInducible T-Cell Co-Stimulator LigandPDS5B protein, humanPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanRepressor ProteinsTNFRSF13B protein, humanTnfrsf13b protein, mouseTNFSF13B protein, humanTranscription FactorsTransmembrane Activator and CAML Interactor Protein

Identifiers

PMID25866827
PMCPMC4381970
OpenAlexW2005478495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.